ArticleAlzheimer's & dementia (Amsterdam, Netherlands)2019
Predicting time to dementia using a quantitative template of disease progression.
Article in Alzheimer's & dementia (Amsterdam, Netherlands), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Trial
- Prediction of alzheimer's disease time to dementia onset using cross-sectional data from spatiotemporal biomarker progression patterns.European journal of nuclear medicine and molecular imaging · 2026Article
- Cross-Dataset Evaluation of Dementia Longitudinal Progression Prediction Models.Human brain mapping · 2025Article
- Independent validation and outlier analysis of EuroPOND alzheimer's disease staging model using ADNI and real-world clinical data.Alzheimer's research & therapy · 2025Article
- Cross-dataset Evaluation of Dementia Longitudinal Progression Prediction Models.medRxiv : the preprint server for health sciences · 2025Article
- Are current etiological theories of Alzheimer's disease falsifiable? An epistemological assessment.Frontiers in aging neuroscience · 2025Article
- Integrating amyloid imaging and genetics for early risk stratification of Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Beyond the usual suspects: multi-factorial computational models in the search for neurodegenerative disease mechanisms.Translational psychiatry · 2024Review
- Data-driven Stochastic Model for Quantifying the Interplay Between Amyloid-beta and Calcium Levels in Alzheimer's Disease.Statistical analysis and data mining · 2024Article
- Machine learning in neurological disorders: A multivariate LSTM and AdaBoost approach to Alzheimer's disease time series analysis.Health care science · 2024Article
- Longitudinal changes in Alzheimer's-related plasma biomarkers and brain amyloid.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023Article
- Disease progression model anchored around clinical diagnosis in longitudinal cohorts: example of Alzheimer's disease and related dementia.BMC medical research methodology · 2023Article
- Predicting age at Alzheimer's dementia onset with the cognitive clock.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023Article
- The temporal event-based model: Learning event timelines in progressive diseases.Imaging neuroscience (Cambridge, Mass.) · 2023Article
- A biomarker-validated time scale in years of disease progression has identified early- and late-onset subgroups in sporadic Alzheimer's disease.Alzheimer's research & therapy · 2023Article
- Longitudinal changes in Alzheimer's-related plasma biomarkers and brain amyloid.medRxiv : the preprint server for health sciences · 2023Article
- Forecasting individual progression trajectories in Alzheimer's disease.Nature communications · 2023Article
- Mapping cerebral atrophic trajectory from amnestic mild cognitive impairment to Alzheimer's disease.Cerebral cortex (New York, N.Y. : 1991) · 2023Article
- Apolipoprotein E ε4 accelerates the longitudinal cerebral atrophy in open access series of imaging studies-3 elders without dementia at enrollment.Frontiers in aging neuroscience · 2023Article
- Targeted Screening for Alzheimer's Disease Clinical Trials Using Data-Driven Disease Progression Models.Frontiers in artificial intelligence · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
introductionCharacterization of longitudinal trajectories of biomarkers implicated in sporadic Alzheimer's disease (AD) in decades before clinical diagnosis is important for disease prevention and monitoring.
methodsWe used a multivariate Bayesian model to temporally align 1369 Alzheimer's disease Neuroimaging Initiative participants based on the similarity of their longitudinal biomarker measures and estimated a quantitative template of the temporal evolution of cerebrospinal fluid A
resultsQuantitative template showed early changes in verbal memory, cerebrospinal fluid Aβ DISCUSSION: Our method provides a quantitative approach for characterizing the natural history of AD starting at preclinical stages despite the lack of individual-level longitudinal data spanning the entire disease timeline.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.